Company intelligence / Profile preview

Siolta Therapeutics

San Carlos, California, United Statessioltatherapeutics.com ↗

Ownership: Private
Employees: ~12
Development stage: Phase 2

Overview

Siolta Therapeutics is advancing multiple programs, with its lead program STMC-103H in Phase 2 for preventing atopic diseases. The company has received a $2.9M NIH grant for manufacturing optimization and a Series C financing of $12 million.

Therapeutic areas: GastroenterologyWomen's HealthImmunologyRare Diseases
Modalities: Live Biotherapeutic Products (LBPs)
Industry: Biotech

Drug pipeline

3 assets

STMC-103H

2 more assets in the full pipeline.

Request access →

Partnerships

Khosla VenturesCowellnex Co. Ltd (Kirin and Kyowa Kirin joint investment)Johns Hopkins University

Beyond the preview

Go deeper on Siolta Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Siolta Therapeutics.

Explore the full profile